Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

linigliptin

- PMLiVE

FDA investigates pancreas risk of diabetes drugs

Products from Merck & Co, BMS, AZ, Novo Nordisk, Boehringer, Amylin and Takeda all involved

- PMLiVE

Informatics to drive clinical trials in UK

Scotland’s chief scientist says NHS data can support medicines research

Astellas files diabetes drug ipragliflozin in Japan

Its SGLT2 inhibitor could beat AZ-BMS' rival Forxiga to debut in that market

- PMLiVE

GSK submits albiglutide for European approval

If approved the diabetes drug will be launched as Eperzan

- PMLiVE

FDA approves J&J’s Bluetooth blood glucose monitor

Licenses iPhone, iPad and iPod Touch compatible monitoring system

- PMLiVE

Novo’s Lantus rival Tresiba hits European markets

Company says its insulin degludec is a more flexible alternative to Sanofi's product

- PMLiVE

Boehringer partners with PatientsLikeMe on rare disease community

Collaborates with the online patient community on idiopathic pulmonary fibrosis

- PMLiVE

Boehringer Ingelheim selects Republica as first US agency of record

Cross-cultural marketing agency wins US business for the pharma company's communications strategy

- PMLiVE

NICE set to turn down Lilly’s lung cancer drug Alimta

Draft guidance doesn't recommend medicine's use as type of maintenance therapy

Sanofi reception

FDA to review Sanofi’s lixisenatide for diabetes

Follows drug's European approval under brand name Lyxumia earlier this month

Mylan to develop Lantus, Humalog and NovoLog generics

Signs Indian biotech deal to compete with the big-selling insulin brands

- PMLiVE

FDA turns down Novo Nordisk’s Tresiba and Ryzodeg

Decision could delay the US launch of the diabetes drugs by two years or more

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links